Sanofi ADS
SNY · Nasdaq
SNY · Nasdaq
Sanofi is a French drug major selling prescription medicines, recently launched products and vaccines, including Dupixent and MenQuadfi. It makes money through product sales, with second-quarter growth driven by Dupixent, newer medicines and cost discipline. MenQuadfi received European Commission approval for use in infants from six weeks of age against specified meningococcal disease. The supplied evidence does not disclose segment contributions, customer mix, total revenue, workforce or geographic scale. It does identify Dupixent as exceeding €5 billion in quarterly sales, providing the clearest disclosed measure of current product scale.
Sanofi ADS fell $2.86, or 6.28%, from $45.54 to $42.68 over the period. The main catalyst was the July 30 second-quarter report: Sanofi beat on earnings and sales, Dupixent exceeded €5 billion in quarterly sales for the first time, and management raised its 2026 outlook, but the shares dropped sharply as investors focused on pipeline setbacks. Volume surged to 10.2 million shares that day, versus 3.5 million the prior session. The stock recovered modestly on July 31, then resumed its decline on August 3-4. Tuesday's European Commission approval expanding MenQuadfi use to infants from six weeks provided no visible offset, with shares closing at a new period low.
Sanofi (SNY) Stock Analysis: Exploring a Potential 25.61% Upside and Robust Dividend YieldGSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
